$325 Million is the total value of Eventide Asset Management's 94 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MDVN | New | MEDIVATION INC | $8,603,000 | – | 134,800 | +100.0% | 2.65% | – |
CBI | New | CHICAGO BRIDGE & IRON CO N V | $8,597,000 | – | 103,400 | +100.0% | 2.65% | – |
TRW | New | TRW AUTOMOTIVE HLDGS CORP | $7,967,000 | – | 107,100 | +100.0% | 2.45% | – |
ABBV | New | ABBVIE INC | $7,842,000 | – | 148,500 | +100.0% | 2.42% | – |
DYAX | New | DYAX CORP | $7,803,000 | – | 1,036,300 | +100.0% | 2.40% | – |
MIC | New | MACQUARIE INFRASTR CO LLCmembership int | $7,604,000 | – | 139,700 | +100.0% | 2.34% | – |
P103PS | New | NPS PHARMACEUTICALS INC | $7,368,000 | – | 242,700 | +100.0% | 2.27% | – |
UFS | New | DOMTAR CORP | $7,283,000 | – | 77,200 | +100.0% | 2.24% | – |
MEOH | New | METHANEX CORP | $7,168,000 | – | 121,000 | +100.0% | 2.21% | – |
RHT | New | RED HAT INC | $7,078,000 | – | 126,300 | +100.0% | 2.18% | – |
LGND | New | LIGAND PHARMACEUTICALS INC | $7,069,000 | – | 134,400 | +100.0% | 2.18% | – |
PCYC | New | PHARMACYCLICS INC | $7,045,000 | – | 66,600 | +100.0% | 2.17% | – |
LEA | New | LEAR CORP | $7,028,000 | – | 86,800 | +100.0% | 2.16% | – |
MGA | New | MAGNA INTL INC | $6,663,000 | – | 81,200 | +100.0% | 2.05% | – |
WBC | New | WABCO HLDGS INC | $6,632,000 | – | 71,000 | +100.0% | 2.04% | – |
LYB | New | LYONDELLBASELL INDUSTRIES N | $6,607,000 | – | 82,300 | +100.0% | 2.04% | – |
NVAX | New | NOVAVAX INC | $6,591,000 | – | 1,287,300 | +100.0% | 2.03% | – |
LLTC | New | LINEAR TECHNOLOGY CORP | $6,536,000 | – | 143,500 | +100.0% | 2.01% | – |
LOW | New | LOWES COS INC | $6,531,000 | – | 131,800 | +100.0% | 2.01% | – |
PANW | New | PALO ALTO NETWORKS INC | $6,529,000 | – | 113,600 | +100.0% | 2.01% | – |
SCTY | New | SOLARCITY CORP | $6,477,000 | – | 114,000 | +100.0% | 2.00% | – |
OII | New | OCEANEERING INTL INC | $6,452,000 | – | 81,800 | +100.0% | 1.99% | – |
EOG | New | EOG RES INC | $6,344,000 | – | 37,800 | +100.0% | 1.95% | – |
BWA | New | BORGWARNER INC | $6,295,000 | – | 112,600 | +100.0% | 1.94% | – |
KAR | New | KAR AUCTION SVCS INC | $6,282,000 | – | 212,600 | +100.0% | 1.94% | – |
CLDX | New | CELLDEX THERAPEUTICS INC NEW | $6,222,000 | – | 257,000 | +100.0% | 1.92% | – |
AYR | New | AIRCASTLE LTD | $6,179,000 | – | 322,500 | +100.0% | 1.90% | – |
SDRL | New | SEADRILL LIMITED | $5,887,000 | – | 143,300 | +100.0% | 1.81% | – |
CPN | New | CALPINE CORP | $5,804,000 | – | 297,500 | +100.0% | 1.79% | – |
NRG | New | NRG ENERGY INC | $5,554,000 | – | 193,400 | +100.0% | 1.71% | – |
FC | New | FRANKLIN COVEY CO | $5,403,000 | – | 271,800 | +100.0% | 1.66% | – |
WAB | New | WABTEC CORP | $5,392,000 | – | 72,600 | +100.0% | 1.66% | – |
New | ASPEN TECHNOLOGY INC | $5,371,000 | – | 128,500 | +100.0% | 1.66% | – | |
STKL | New | SUNOPTA INC | $5,345,000 | – | 534,000 | +100.0% | 1.65% | – |
AGIO | New | AGIOS PHARMACEUTICALS INC | $5,001,000 | – | 208,800 | +100.0% | 1.54% | – |
ASML | New | ASML HOLDING N V | $4,872,000 | – | 52,000 | +100.0% | 1.50% | – |
SUNEQ | New | SUNEDISON INC | $4,866,000 | – | 372,900 | +100.0% | 1.50% | – |
PTLA | New | PORTOLA PHARMACEUTICALS INC | $4,462,000 | – | 173,300 | +100.0% | 1.38% | – |
IPHI | New | INPHI CORP | $4,413,000 | – | 342,100 | +100.0% | 1.36% | – |
ACAD | New | ACADIA PHARMACEUTICALS INC | $4,383,000 | – | 175,400 | +100.0% | 1.35% | – |
PBYI | New | PUMA BIOTECHNOLOGY INC | $4,359,000 | – | 42,100 | +100.0% | 1.34% | – |
STML | New | STEMLINE THERAPEUTICS INC | $4,079,000 | – | 208,100 | +100.0% | 1.26% | – |
NOV | New | NATIONAL OILWELL VARCO INC | $3,778,000 | – | 47,500 | +100.0% | 1.16% | – |
SJM | New | SMUCKER J M CO | $3,741,000 | – | 36,100 | +100.0% | 1.15% | – |
NLNK | New | NEWLINK GENETICS CORP | $3,462,000 | – | 157,300 | +100.0% | 1.07% | – |
CCI | New | CROWN CASTLE INTL CORP | $3,290,000 | – | 44,800 | +100.0% | 1.01% | – |
CMRE | New | COSTAMARE INC | $3,192,000 | – | 174,700 | +100.0% | 0.98% | – |
SGMO | New | SANGAMO BIOSCIENCES INC | $3,018,000 | – | 217,300 | +100.0% | 0.93% | – |
SRPT | New | SAREPTA THERAPEUTICS INC | $2,888,000 | – | 141,800 | +100.0% | 0.89% | – |
SZYM | New | SOLAZYME INC | $2,627,000 | – | 241,200 | +100.0% | 0.81% | – |
PWR | New | QUANTA SVCS INC | $2,496,000 | – | 79,100 | +100.0% | 0.77% | – |
DWSN | New | DAWSON GEOPHYSICAL CO | $2,208,000 | – | 65,300 | +100.0% | 0.68% | – |
TSLA | New | TESLA MTRS INC | $2,150,000 | – | 14,300 | +100.0% | 0.66% | – |
SAAS | New | INCONTACT INC | $1,510,000 | – | 193,300 | +100.0% | 0.46% | – |
COG | New | CABOT OIL & GAS CORP | $1,364,000 | – | 35,200 | +100.0% | 0.42% | – |
TTPH | New | TETRAPHASE PHARMACEUTICALS I | $1,306,000 | – | 96,600 | +100.0% | 0.40% | – |
ATRC | New | ATRICURE INC | $1,295,000 | – | 69,300 | +100.0% | 0.40% | – |
ININ | New | INTERACTIVE INTELLIGENCE GRO | $1,010,000 | – | 15,000 | +100.0% | 0.31% | – |
SHPG | New | SHIRE PLCsponsored adr | $904,000 | – | 6,400 | +100.0% | 0.28% | – |
MDSO | New | MEDIDATA SOLUTIONS INC | $848,000 | – | 14,000 | +100.0% | 0.26% | – |
CBST | New | CUBIST PHARMACEUTICALS INC | $820,000 | – | 11,900 | +100.0% | 0.25% | – |
XOMA | New | XOMA CORP DEL | $818,000 | – | 121,600 | +100.0% | 0.25% | – |
SLXP | New | SALIX PHARMACEUTICALS INC | $809,000 | – | 9,000 | +100.0% | 0.25% | – |
CEMP | New | CEMPRA INC | $797,000 | – | 64,300 | +100.0% | 0.25% | – |
CSII | New | CARDIOVASCULAR SYS INC DEL | $782,000 | – | 22,800 | +100.0% | 0.24% | – |
PCRX | New | PACIRA PHARMACEUTICALS INC | $765,000 | – | 13,300 | +100.0% | 0.24% | – |
RGEN | New | REPLIGEN CORP | $732,000 | – | 53,700 | +100.0% | 0.23% | – |
BMRN | New | BIOMARIN PHARMACEUTICAL INC | $731,000 | – | 10,400 | +100.0% | 0.22% | – |
AMBI | New | AMBIT BIOSCIENCES CORP | $714,000 | – | 74,100 | +100.0% | 0.22% | – |
NTUS | New | NATUS MEDICAL INC DEL | $693,000 | – | 30,800 | +100.0% | 0.21% | – |
KPTI | New | KARYOPHARM THERAPEUTICS INC | $678,000 | – | 29,600 | +100.0% | 0.21% | – |
OMED | New | ONCOMED PHARMACEUTICALS INC | $664,000 | – | 22,500 | +100.0% | 0.20% | – |
CERS | New | CERUS CORP | $631,000 | – | 97,800 | +100.0% | 0.19% | – |
HPTX | New | HYPERION THERAPEUTICS INC | $631,000 | – | 31,200 | +100.0% | 0.19% | – |
BRKR | New | BRUKER CORP | $605,000 | – | 30,600 | +100.0% | 0.19% | – |
ACRX | New | ACELRX PHARMACEUTICALS INC | $599,000 | – | 53,000 | +100.0% | 0.18% | – |
INSM | New | INSMED INC | $560,000 | – | 32,900 | +100.0% | 0.17% | – |
TFX | New | TELEFLEX INC | $544,000 | – | 5,800 | +100.0% | 0.17% | – |
ATHN | New | ATHENAHEALTH INC | $538,000 | – | 4,000 | +100.0% | 0.17% | – |
BLUE | New | BLUEBIRD BIO INC | $539,000 | – | 25,700 | +100.0% | 0.17% | – |
FEIC | New | FEI CO | $536,000 | – | 6,000 | +100.0% | 0.16% | – |
MDAS | New | MEDASSETS INC | $525,000 | – | 26,500 | +100.0% | 0.16% | – |
RPTP | New | RAPTOR PHARMACEUTICAL CORP | $526,000 | – | 40,400 | +100.0% | 0.16% | – |
MGNX | New | MACROGENICS INC | $521,000 | – | 19,000 | +100.0% | 0.16% | – |
MEIP | New | MEI PHARMA INC | $497,000 | – | 62,100 | +100.0% | 0.15% | – |
ECYT | New | ENDOCYTE INC | $489,000 | – | 45,700 | +100.0% | 0.15% | – |
RMD | New | RESMED INC | $466,000 | – | 9,900 | +100.0% | 0.14% | – |
ATHX | New | ATHERSYS INC | $443,000 | – | 177,100 | +100.0% | 0.14% | – |
SNSS | New | SUNESIS PHARMACEUTICALS INC | $435,000 | – | 91,800 | +100.0% | 0.13% | – |
NBIX | New | NEUROCRINE BIOSCIENCES INC | $360,000 | – | 38,500 | +100.0% | 0.11% | – |
HTWR | New | HEARTWARE INTL INC | $291,000 | – | 3,100 | +100.0% | 0.09% | – |
FMI | New | FOUNDATION MEDICINE INC | $274,000 | – | 11,500 | +100.0% | 0.08% | – |
ONTX | New | ONCONOVA THERAPEUTICS INC | $264,000 | – | 23,000 | +100.0% | 0.08% | – |
VVUS | New | VIVUS INC | $253,000 | – | 27,900 | +100.0% | 0.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-02-11
About Eventide Asset Management
Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.
The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.
The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.
Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.
Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
LOWES COS INC | 40 | Q3 2023 | 3.2% |
PALO ALTO NETWORKS INC | 40 | Q3 2023 | 3.6% |
ASML HOLDINGS NV | 40 | Q3 2023 | 1.9% |
NEUROCRINE BIOSCIENCES INC | 40 | Q3 2023 | 1.1% |
REPLIGEN CORP | 40 | Q3 2023 | 0.5% |
VERACYTE INC | 38 | Q3 2023 | 1.5% |
LAM RESEARCH CORP | 35 | Q3 2023 | 3.4% |
XPO LOGISTICS INC | 34 | Q1 2023 | 3.8% |
COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.6% |
MAGNA INTL INC | 33 | Q4 2021 | 2.5% |
View Eventide Asset Management's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Cogent Biosciences, Inc. | February 14, 2023 | 2,589,778 | 3.7% |
ESSA Pharma Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Freeline Therapeutics Holdings plc | February 14, 2023 | 5,920,765 | 9.1% |
KnowBe4, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Praxis Precision Medicines, Inc. | February 14, 2023 | 3,518,062 | 7.5% |
Prometheus Biosciences, Inc. | February 14, 2023 | 1,032,938 | 2.2% |
SUTRO BIOPHARMA, INC.Sold out | February 14, 2023 | 0 | 0.0% |
Vital Farms, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Zymeworks Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Entasis Therapeutics Holdings Inc. | February 14, 2022 | 590,602 | 1.2% |
View Eventide Asset Management's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR/A | 2024-02-20 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Eventide Asset Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.